- Home
- CCEL vs AKTX Comparison
CCEL vs AKTX Comparison
Compare CCEL & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCEL
- AKTX
- Stock Information
- Founded
- CCEL 1989
- AKTX N/A
- Country
- CCEL United States
- AKTX United States
- Employees
- CCEL N/A
- AKTX N/A
- Industry
- CCEL Managed Health Care
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- CCEL Health Care
- AKTX Health Care
- Exchange
- CCEL Nasdaq
- AKTX Nasdaq
- Market Cap
- CCEL 39.9M
- AKTX 41.8M
- IPO Year
- CCEL 1997
- AKTX N/A
- Fundamental
- Price
- CCEL $5.13
- AKTX $1.12
- Analyst Decision
- CCEL Strong Buy
- AKTX
- Analyst Count
- CCEL 1
- AKTX 0
- Target Price
- CCEL $8.50
- AKTX N/A
- AVG Volume (30 Days)
- CCEL 8.3K
- AKTX 25.3K
- Earning Date
- CCEL 07-14-2025
- AKTX 08-18-2025
- Dividend Yield
- CCEL 7.97%
- AKTX N/A
- EPS Growth
- CCEL N/A
- AKTX N/A
- EPS
- CCEL 0.01
- AKTX N/A
- Revenue
- CCEL $32,102,750.00
- AKTX N/A
- Revenue This Year
- CCEL $2.49
- AKTX N/A
- Revenue Next Year
- CCEL $0.95
- AKTX N/A
- P/E Ratio
- CCEL $555.99
- AKTX N/A
- Revenue Growth
- CCEL 2.33
- AKTX N/A
- 52 Week Low
- CCEL $4.75
- AKTX $0.85
- 52 Week High
- CCEL $9.43
- AKTX $4.40
- Technical
- Relative Strength Index (RSI)
- CCEL 50.16
- AKTX 47.22
- Support Level
- CCEL $5.00
- AKTX $1.08
- Resistance Level
- CCEL $5.31
- AKTX $1.25
- Average True Range (ATR)
- CCEL 0.22
- AKTX 0.08
- MACD
- CCEL 0.02
- AKTX -0.01
- Stochastic Oscillator
- CCEL 43.09
- AKTX 39.71
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.